GTC
ESPR

Ghost Tree Capital’s Esperion Therapeutics ESPR Stock Holding History

Ghost Tree Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-230,000
Closed -$15.1M – 57
2017
Q4 		$15.1M Buy
+230,000
New +$12.4M 3.55% 6
2015
Q3 		– Sell
-75,000
Closed -$6.13M – 84
2015
Q2 		$6.13M Buy
+75,000
New +$7.34M 1.99% 16

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ghost Tree Capital's ESPR Position: Q1 2018 in Review

Ghost Tree Capital sold out of Esperion Therapeutics (ESPR) in Q1 2018, closing a stake of 230,000 shares — an estimated $15.1M sold.

Ghost Tree Capital first reported a position in ESPR in Q2 2015 and held it in 2 quarters. The position peaked at $15.1M in Q4 2017. 187 funds tracked by Wall St. Rank hold ESPR as of Q1 2018.

  • Ghost Tree Capital reported no remaining Esperion Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ghost Tree Capital sold 230,000 Esperion Therapeutics shares in Q1 2018, an estimated $15.1M.
  • Ghost Tree Capital first reported a position in Esperion Therapeutics in Q2 2015 and held it in 2 quarters.
  • Ghost Tree Capital's Esperion Therapeutics position peaked at $15.1M in Q4 2017.
  • 187 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2018.

Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.